Quantitative benefit–risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma

Background: Quantitative drug benefit–risk assessment (BRA) helps assess the magnitude of benefit and risk of new cancer therapies. This BRA aimed to summarize the evidence for the benefits and risks of ivosidenib versus placebo for the treatment of previously treated, locally advanced or metastatic...

Повний опис

Бібліографічні деталі

Автори:	J.W. Valle, G.K. Abou-Alfa, R.K. Kelley, M.A. Lowery, R.T. Shroff, Y. Bian, G. Saint-Hilary, H. Liu, Z. Teng, Z. Hua, C. Gliser, A. Vogel, M.M. Javle
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Elsevier 2025-06-01
Серія:	ESMO Gastrointestinal Oncology
Предмети:	quantitative drug benefit–risk assessment cholangiocarcinoma mutant isocitrate dehydrogenase-1 ivosidenib
Онлайн доступ:	http://www.sciencedirect.com/science/article/pii/S2949819825000287
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!